Banco Bilbao Vizcaya Argentaria S.A. Buys 18,244 Shares of Bristol Myers Squibb Company $BMY

Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Bristol Myers Squibb Company (NYSE:BMY) by 2.9% during the 3rd quarter, Holdings Channel reports. The firm owned 656,339 shares of the biopharmaceutical company’s stock after buying an additional 18,244 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.’s holdings in Bristol Myers Squibb were worth $29,595,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb in the second quarter valued at about $25,000. Harbor Capital Advisors Inc. increased its holdings in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. Total Investment Management Inc. acquired a new stake in shares of Bristol Myers Squibb during the second quarter worth approximately $38,000. Twin Peaks Wealth Advisors LLC bought a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $40,000. Finally, Bank of Jackson Hole Trust boosted its holdings in shares of Bristol Myers Squibb by 352.2% in the 3rd quarter. Bank of Jackson Hole Trust now owns 1,040 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 810 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.1%

Shares of BMY opened at $59.02 on Friday. The stock’s fifty day simple moving average is $58.24 and its 200-day simple moving average is $51.43. The firm has a market capitalization of $120.18 billion, a PE ratio of 17.11, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). The firm had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.Bristol Myers Squibb’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Investors of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is 73.04%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research note on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Finally, Citigroup lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $61.00.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.